After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q2 CY2025, but sales were flat year on year at $213.1 ...

Gross margin of 71.2% increased over 160 basis points year-over-year, and optimism for new product lines, In Q1 2025, revenue declined by 3% year-over-year, but excluding headwinds of $16 million, ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Tuesday after market hours.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Tuesday reported a loss of $330.5 million in its second quarter. The Salt Lake City-based company said it had a loss of $3.57 ...

Analysts are estimating that Myriad Genetics will report an earnings per share (EPS) of $-0.05. Investors in Myriad Genetics ...

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

In the second quarter of 2025, Myriad Genetics initiated a review of its long-range growth strategy. While the updated strategy, which is designed to drive accelerated growth and profitability by ...

Looking at Myriad Genetics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Gilead Sciences delivered year-on-year ...

Puneet Souda has given his Buy rating due to a combination of factors including the successful transformation of Myriad Genetics and its solid performance in the recent quarter. The company not ...

Myriad Genetics, the company that once held patents on human genes, is now suing two rivals who are conducting gene tests using its other patents not banned by the Supreme Court.